See more : Ruijie Networks Co., Ltd. (301165.SZ) Income Statement Analysis – Financial Results
Complete financial analysis of Polydex Pharmaceuticals Limited (POLXF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Polydex Pharmaceuticals Limited, a leading company in the Biotechnology industry within the Healthcare sector.
- Big Gold Inc. (BG.CN) Income Statement Analysis – Financial Results
- Continental Aktiengesellschaft (CTTAF) Income Statement Analysis – Financial Results
- Mentice AB (publ) (MNTC.ST) Income Statement Analysis – Financial Results
- Clarkson PLC (CKN.L) Income Statement Analysis – Financial Results
- Hang Tai Yue Group Holdings Limited (8081.HK) Income Statement Analysis – Financial Results
Polydex Pharmaceuticals Limited (POLXF)
About Polydex Pharmaceuticals Limited
Polydex Pharmaceuticals Limited, through its subsidiaries, develops, manufactures, and markets biotechnology-based products for the human pharmaceutical market worldwide. The company also manufactures bulk pharmaceutical intermediates for the veterinary pharmaceutical industry. It primarily offers dextran and derivative products, including iron dextran, a derivative of dextran that is injected into pigs at birth as a treatment for anemia; and dextran sulphate, a specialty chemical derivative of dextran used in biotechnology applications and the pharmaceutical industry. In addition, the company develops Ushercell, a high molecular weight cellulose sulphate for topical vaginal use primarily in the prevention and transmission of AIDS and other sexually transmitted diseases, as well as unplanned pregnancies. Further, it supplies ferric hydroxide and hydrogenated dextran solutions. The company sells its products through independent distributors and wholesalers, as well as directly to companies. The company was formerly known as Polydex Chemicals Limited and changed its name to Polydex Pharmaceuticals Limited in March 1984. Polydex Pharmaceuticals Limited was incorporated in 1979 and is based in Toronto, Canada.
| Metric | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4.48M | 4.82M | 5.73M | 6.50M | 5.27M | 6.37M | 14.09M | 12.79M | 12.17M | 13.65M | 13.10M | 11.70M | 9.80M | 9.30M | 8.50M | 7.30M | 7.00M | 4.40M | 3.50M | 2.20M | 2.00M | 3.30M |
| Cost of Revenue | 4.57M | 4.79M | 5.36M | 5.67M | 4.84M | 4.39M | 10.74M | 9.53M | 9.43M | 10.00M | 9.47M | 8.00M | 6.90M | 6.90M | 6.90M | 6.00M | 6.00M | 3.10M | 2.60M | 2.00M | 1.50M | 2.60M |
| Gross Profit | -91.73K | 31.90K | 375.06K | 832.44K | 429.19K | 1.98M | 3.35M | 3.26M | 2.74M | 3.65M | 3.62M | 3.70M | 2.90M | 2.40M | 1.60M | 1.30M | 1.00M | 1.30M | 900.00K | 200.00K | 500.00K | 700.00K |
| Gross Profit Ratio | -2.05% | 0.66% | 6.54% | 12.81% | 8.15% | 31.14% | 23.77% | 25.48% | 22.49% | 26.73% | 27.67% | 31.62% | 29.59% | 25.81% | 18.82% | 17.81% | 14.29% | 29.55% | 25.71% | 9.09% | 25.00% | 21.21% |
| Research & Development | 4.49K | 35.10K | 135.82K | 214.87K | 205.80K | 114.74K | 60.95K | 172.10K | 464.61K | 1.11M | 637.32K | 0.00 | 200.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 907.64K | 1.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 57.96K | 67.57K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 965.59K | 1.07M | 1.21M | 1.38M | 1.55M | 1.57M | 2.10M | 1.80M | 1.67M | 1.78M | 1.72M | 1.90M | 2.00M | 1.60M | 1.70M | 1.80M | 1.50M | 1.00M | 900.00K | 1.30M | 1.80M | 1.30M |
| Other Expenses | 124.99K | 34.48K | 39.97K | 42.19K | 61.16K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 1.10M | 1.14M | 1.39M | 1.63M | 1.82M | 2.19M | 2.77M | 2.81M | 2.81M | 3.59M | 2.87M | 2.40M | 2.80M | 2.20M | 2.30M | 2.40M | 2.10M | 1.30M | 1.20M | 1.80M | 2.20M | 1.70M |
| Cost & Expenses | 5.67M | 5.93M | 6.75M | 7.30M | 6.65M | 6.58M | 13.52M | 12.34M | 12.24M | 13.59M | 12.35M | 10.40M | 9.70M | 9.10M | 9.20M | 8.40M | 8.10M | 4.40M | 3.80M | 3.80M | 3.70M | 4.30M |
| Interest Income | 11.19K | 10.36K | 103.78K | 497.66K | 148.17K | 0.00 | 0.00 | 0.00 | 37.80K | 217.08K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 54.62K | 66.71K | 96.82K | 94.79K | 81.51K | 91.21K | 133.38K | 150.53K | 206.05K | 286.78K | 147.99K | 100.00K | 100.00K | 200.00K | 0.00 | 100.00K | 100.00K | 100.00K | 100.00K | 200.00K | 200.00K | 100.00K |
| Depreciation & Amortization | 429.68K | 549.38K | 522.08K | 524.89K | 557.47K | 513.10K | 617.69K | 572.13K | 548.93K | 601.70K | 519.80K | 500.00K | 600.00K | 600.00K | 600.00K | 600.00K | 600.00K | 300.00K | 300.00K | 500.00K | 400.00K | 400.00K |
| EBITDA | -745.93K | -1.51M | -489.83K | -276.68K | -831.04K | -1.70M | 2.03M | 1.51M | 395.43K | 477.11K | 1.03M | 1.70M | 1.20M | 700.00K | 200.00K | -600.00K | -400.00K | 400.00K | -100.00K | -1.40M | -1.20M | -300.00K |
| EBITDA Ratio | -16.65% | -31.23% | -8.54% | -4.26% | -15.78% | -26.75% | 14.40% | 11.79% | 3.25% | 3.50% | 7.86% | 14.53% | 12.24% | 7.53% | 2.35% | -8.22% | -5.71% | 9.09% | -2.86% | -63.64% | -60.00% | -9.09% |
| Operating Income | -1.18M | -2.06M | -1.01M | -801.57K | -1.39M | -209.95K | 574.75K | 449.74K | -75.70K | 57.81K | 749.95K | 1.30M | 100.00K | 200.00K | -700.00K | -1.10M | -1.10M | 100.00K | -300.00K | -1.60M | -1.70M | -1.00M |
| Operating Income Ratio | -26.23% | -42.62% | -17.64% | -12.33% | -26.37% | -3.29% | 4.08% | 3.52% | -0.62% | 0.42% | 5.73% | 11.11% | 1.02% | 2.15% | -8.24% | -15.07% | -15.71% | 2.27% | -8.57% | -72.73% | -85.00% | -30.30% |
| Total Other Income/Expenses | -969.13K | -237.53K | 44.75K | 636.08K | 80.22K | -1.10M | 1.92M | -970.72K | -487.63K | 37.80K | 92.44K | -100.00K | -100.00K | 100.00K | -300.00K | -300.00K | -100.00K | -100.00K | 0.00 | -1.00M | -200.00K | -300.00K |
| Income Before Tax | -2.14M | -1.64M | -967.16K | -375.82K | -1.31M | 1.71M | -395.97K | 77.63K | -37.90K | 274.89K | 842.40K | 1.20M | -400.00K | 300.00K | -1.00M | -1.00M | -1.20M | -300.00K | -400.00K | -1.30M | -1.80M | -1.30M |
| Income Before Tax Ratio | -47.86% | -34.08% | -16.86% | -5.78% | -24.85% | 26.78% | -2.81% | 0.61% | -0.31% | 2.01% | 6.43% | 10.26% | -4.08% | 3.23% | -11.76% | -13.70% | -17.14% | -6.82% | -11.43% | -59.09% | -90.00% | -39.39% |
| Income Tax Expense | 54.62K | -52.96K | -81.94K | -115.20K | 180.76K | 566.87K | -389.97K | 751.37K | 168.98K | 143.60K | -127.45K | 600.00K | -900.00K | 100.00K | 500.00K | -100.00K | 100.00K | 100.00K | 100.00K | 600.00K | 400.00K | 300.00K |
| Net Income | -2.20M | -1.59M | -885.21K | -260.62K | -1.49M | 1.14M | -6.00K | -673.74K | -206.88K | 131.28K | 969.84K | 600.00K | 500.00K | 100.00K | -1.20M | -1.00M | -1.20M | -300.00K | -700.00K | -2.20M | -2.10M | -1.30M |
| Net Income Ratio | -49.08% | -32.98% | -15.44% | -4.01% | -28.28% | 17.89% | -0.04% | -5.27% | -1.70% | 0.96% | 7.41% | 5.13% | 5.10% | 1.08% | -14.12% | -13.70% | -17.14% | -6.82% | -20.00% | -100.00% | -105.00% | -39.39% |
| EPS | 0.00 | -0.52 | -0.29 | -0.09 | -0.49 | 0.38 | 0.00 | -0.22 | -0.07 | 0.04 | 0.32 | 0.19 | 0.17 | 0.04 | -0.42 | -0.40 | -0.50 | -0.10 | -0.30 | -1.10 | -1.30 | -0.90 |
| EPS Diluted | 0.00 | -0.52 | -0.29 | -0.09 | -0.49 | 0.37 | 0.00 | -0.22 | -0.07 | 0.04 | 0.32 | 0.19 | 0.17 | 0.04 | -0.42 | -0.40 | -0.50 | -0.10 | -0.30 | -1.10 | -1.30 | -0.90 |
| Weighted Avg Shares Out | 0.00 | 3.07M | 3.07M | 3.06M | 3.04M | 3.00M | 3.00M | 3.03M | 2.96M | 3.28M | 3.03M | 3.00M | 2.92M | 2.82M | 2.82M | 2.50M | 2.40M | 3.00M | 2.33M | 2.00M | 1.62M | 1.44M |
| Weighted Avg Shares Out (Dil) | 0.00 | 3.07M | 3.07M | 3.06M | 3.04M | 3.08M | 3.03M | 3.06M | 2.96M | 3.28M | 3.03M | 3.00M | 2.92M | 2.82M | 2.86M | 2.50M | 2.40M | 3.00M | 2.33M | 2.00M | 1.62M | 1.44M |
Polydex Pharmaceuticals Limited and BioSpectra Inc. Announce Business Combination
Polydex Pharmaceuticals Limited Shareholders Vote to Approve BioSpectra Inc. Business Combination
Source: https://incomestatements.info
Category: Stock Reports